1. Methods: Efficacy data from 10 Phase 3 trials (n¼4915) were pooled into 4 groups ac-
cording to ALI dose, control (placebo/ezetimibe) and use of background statin therapy.
Two studies used a dose of ALI 150 mg every 2 weeks (Q2W); 8 studies used 75 mg Q2W
with the dose increase to 150 mg Q2W at week 12 depending on week 8 LDL-C. Safety
data for those with/without HTN were compared (n¼4974).
Results: Treatment with ALI resulted in similar significant LDL-C reductions in those with
HTN as well as those without HTN (Figure). ALI safety was comparable to controls in each
subgroup (Table).
Conclusion: Across the ODYSSEY program, ALI is a potent therapy for LDL-C reduction in
those with HTN and is well tolerated.
Disclosure of Interest: R. Santos Consultancy for: AstraZeneca, Amgen, Biolab, Boeh-
ringer-Ingelheim, Cerenis, Eli-Lilly, Kowa, Genzyme, Pfizer, Praxis, Sanofi/Regeneron,
Unilever, Speakers bureau: AstraZeneca, Amgen, Aegerion, Biolab, Boehringer-Ingelheim,
Cerenis, Eli-Lilly, Kowa, Genzyme, Pfizer, Praxis, Sanofi/Regeneron, Torrent, Unilever, K.
Ferdinand Grant/research support from: Boehringer Ingelheim, Consultancy for: Boeh-
ringer Ingelheim,Lilly, Amgen,Sanofi, Honorarium from: Amgen,Sanofi, R. S. Wright
Consultancy for: Astra Zeneca, Pfizer, The Medicines Co. Regeneron, Sanofi, Boehringer
Ingelheim, E. P. Navarese Honorarium from: Sanofi/Regeneron, M. Louie Shareholder of:
Regeneron, Employee from: Regeneron, L. V. Lee Employee from: Sanofi, G. Asset
Shareholder of: Sanofi, Employee from: Sanofi, J. Robinson Grant/research support from:
Research grants to institution from: Amarin, Amgen, Astra-Zeneca, Eli Lilly, Esai, Glaxo-
Smith Kline, Merck, Pfizer, Regeneron/Sanofi, Takeda, Consultancy for: Amgen, Eli Lilly,
Merck, Pfizer, Regeneron/Sanofi
PM073
Gender Features of Myocardial Electrical Instability in Patients With Arterial
Hypertension and Metabolic Syndrome
B. G. Hodjakuliyev1
, B. N. Orayeva1
, M. B. Muhammedov*1
1
hospital therapy, Turkmen state medical university, Ashgabad, Turkmenistan
Introduction: The purpose - analysis of myocardial electrical instability in patients with
metabolic syndrome (MS) and arterial hypertension (AH).
Objectives: The purpose - analysis of myocardial electrical instability in patients with
metabolic syndrome (MS) and arterial hypertension (AH).
Methods: The study included 30 patients with AH and 35 patients with MS. All surveyed
was conducted Holter monitoring (HM) and Echocardiography.
Results: In men with MS, compared to women, observed a longer anamnesis of obesity
and hypertension. Echocardiography rates in MS patients not different from the com-
parison group. During the HM the frequency of single premature atrial contraction (PAC)
was similar in patients with MS and control group, but the couple PACs (women -
37.83%, men - 42.47% ) and group PACs (women - 12.5%, men - 43.47% )). And single
premature ventricule contraction (PVC) ( women - 37.93%, men - 66.6% ) and couple
PVCs (women - 6.78% men - 7.7% ) ) significantly more frequently found in patients
with MS. Group PVCs (3.44%) were observed only in patients with MS. Men with MS
had higher frequency of PACs and PVCs compared with women. Analysis of heart rate
variability (HRV) - for patients with MS had significantly lower values of SDNN,
RMMSD, power at low and high frequencies, which is an unfavorable sign and reflects
the decrease in the activity of parasympathetic regulation of the heart rhythm. There
were also gender differences HRV: men with MS revealed lower values of the time pa-
rameters when compared with women. Furthermore, they had lower values of power at
high frequencies and high values of power at low frequencies. Patients with MS were also
characterized by a higher inhomogeneity of ventricular repolarization compared with a
group of patients with hypertension. Women and men with MS QT interval was 382,0 Æ
10,79 ms and 409,35 Æ 10,05 ms, interval dispersion QT - 79,0 Æ 7,6 ms and 59,21 Æ
8,1 ms, respectively. Rate of ventricular repolarization in patients with hypertension had
lower values.
Conclusion: Thus, MS is associated with increased myocardial electric instability of auricle
and ventricles, which is manifested a higher frequency of arrhythmias in violation of the
vegetative regulation processes of heart rhythm, increasing inhomogeneity of ventricular
repolarization.
Disclosure of Interest: None Declared
PM076
Erectile Dysfunction Was Not Related With the Arterial Stiffness
V. Dzenkeviciute*1,2
, M. Petrylaite3
, E. Rinkuniene2,4
, Z. Petrulioniene2,4
, A. Laucevicius2,5
,
J. Badariene2,4
, A. Cypiene2,6
1
Clinic of Internal medicine, Oncology and Family medicine; Vilnius, Lithuania, Vilnius
University, 2
Clinic of Heart and Vascular medicine, Vilnius, Lithuania, Vilnius University
Hospital Santariskiu klinikos, 3
Medical faculty, 4
Clinic of Heart and Vascular medicine, Vilnius,
Lithuania, 5
Experimental and Clinical Medicine Research Institute, 6
Experimental and Clinical
Medicine Research Institute, Vilnius University, Vilnius, Lithuania
Introduction: Erectile dysfunction (ED) is identified as a possible early atherosclerosis
marker. Cardio ankle vascular index (CAVI) is also an effective predictor of cardiovascular
disease and vascular age.
Objectives: The aim of the study was to explore the relationship between erectile
dysfunction and CAVI, beyond traditional risk factors.
Methods: 118 asymptomatic men aged 40-55 years were included in this case-control
study. International Index of Erectile Function (IIEF) was used to assess erectile function.
60 (50.8%) men with mean age 47.05 Æ 3.88 was allocated into erectile dysfunction group
and 58 (49.2%) men with a mean age 46.16 Æ 4.34 in the control group. CAVI mea-
surements with VaSera VS-100 were performed. Cardiovascular risk factors as smoking,
diabetes mellitus, body mass index, blood pressure as well as biochemical parameters (low
density lipoprotein cholesterol, high density lipoprotein-cholesterol, triglycerides, fasting
glucose, eGFR, albumin/creatinine ratio) were also obtained. Total patient risk was
calculated with high CV risk EuroHeartScore.
Results: Mean IIEF score in patients with ED was 18.07Æ3.07; in the control group –
23.52 Æ 1.06. In patients with ED significantly higher EuroHeartScore index (3.00Æ2.65
vs. 1.64Æ1.41, p¼0.006) and lower eGFR (86.96Æ8.14 vs. 88.88 Æ3.78, p¼0.02) were
observed. No significant difference in CAVI was found between the two study groups (7.1
vs. 6.56, p>0.05) as well as other CV risk factors.
In multiple regression analysis only HDL-cholesterol (ß¼0.227, p¼ 0.012) and Euro-
HeartScore (ß¼-0.234, p¼ 0.013) were recognized as an independent risk factor for ED
severity . No relationship between erectile dysfunction and CAVI were found.
Conclusion: ED severity was positively associated with higher EuroHeartScore and lower
HDL-cholesterol, but not with CAVI.
Disclosure of Interest: None Declared
PM079
Postmenopausal Metabolic Syndrome and Vascular Characteristics: Influence of
Hypoglycemic Drugs
O. A. Kislyak*1
, A. V. Starodubova1
, J. B. Chervjakova1
, A. A. Kopelev1
1
Department of internal medicine, Russian National Research Medical University, Moscow,
Russian Federation
Introduction: Metabolic syndrome (MS) in postmenopausal women is a common state
with high risk of diabetes mellitus and cardiovascular morbility and mortality. The
importance of correction of dyslipidemia, glycemic and blood pressure control in these
subjects is obvious. The most interesting topic of these interventions is the ability of hy-
poglycemic drugs (HD) to influence the characteristics of MS and vascular characteristics
(VC).
Objectives: The aim of the investigation was to evaluate the impact of HD on the main
features of MS and VC in postmenopausal women.
Methods: Body mass (BM) (kg) and BM index (BMI) (kg/m 2); waist (WC) and hip (HC)
circumference (sm); total cholesterol (TC), triglycerides (TG), fasting plasma glucose (FG)
(mmol/l); C-peptide (pmol/l); insulin (mcU/ml); leptin (ng/dl); carotid–femoral pulse wave
velocity (PWV) (m/sec); carotid intima–media thickness (IMT CA) (mm); femoral intima–
media thickness (IMT FA) (mm).
Results: 51 women with postmenopausal MS and impaired glucose tolerance (IGT) were
treated with HD for 12 weeks (metformin 850 mg/day 15 women; rosiglitazone 4mg/day
18 women and acarbose 150 mg/day 18 women). Metformin treatment led to reduction of
BM (p¼0,005), WC (p¼0,005), HC (p¼0,02), FG (p¼0,02), C-peptide in oral glucose
tolerance test (OGTT) (p¼0,003), insulin in OGTT (p¼0,02), TC (p¼0,01), TG
(p¼0,003), leptin (p<0,05); IMT CA (p<0,05). Rosiglitazone treatment led to reduction of
IMT CA and IMT FA (p<0,05) with no significant reduction of leptin, indicators of lipid
and carbohydrate metabolism and anthropometric indices, BM increased in 28% of
women. Acarbose treatment led to reduction of BM (p¼0,01), BMI (p¼0,003), WC
(p¼0,009), HC (p¼0,003), C-peptide in OGTT(p¼0,0001), fasting insulin (p¼0,01),
insulin in OGTT (p¼0,01), leptin (p<0,05), IMT FA (p<0,05), PWV (p<0,05) with no
significant changes in lipid metabolism.
Conclusion: Treatment with HD in women with postmenopausal MS and IGT can to some
extent improve the VC (IMT CA, IMT FA and PWV). The greatest impact on anthropometric
indices, carbohydrate metabolism and leptin had metformin and acarbose. Only metformin
demonstrated the abiity to cause significant changes in indicators of lipid metabolism.
Disclosure of Interest: None Declared
PM080
A Study of Adult Out of Hospital Cardiac Arrests in an Indian Population
S. Ramaka*1,2
, M. Machavarapu3
, P. Chodavarapu4
, V. Ramaka5
, R. Garipelly6
, H. B. Rao7
,
R. Chodavarapu8
1
Cardiology, Srinivasa Heart Centre, 2
Srinivasa Heart Foundation, 3
Kakatiya Medical College,
Warangal, India, 4
Clinical Research Fellow, Department of Outcomes Research, Cleveland
Clinic, Cleveland, United States, 5
Siddhartha Medical College, Vijayawada, 6
Pharmacy,
St.Peter’s Institute of Pharmaceutical Sciences, Warangal, 7
Cardiology, Krishna Institute of
Medical Sciences Hospital, Hyderabad, 8
Paediatrics, Dr.Pinnamaneni Siddhartha Institute of
Medical Sciences&Research Foundation, Vijayawada, India
Introduction: Out Of Hospital Cardiac Arrest is an important public health problem
worldwide.Studies on Out- Of- Hospital Cardiac Arrest (OOHCA) are limited in India.
Objectives: To study the demographic and clinical profile of victims of Out- Of- Hospital
Cardiac Arrest.
e82 GHEART Vol 11/2S/2016 j June, 2016 j POSTER/WCC_2016-POSTERS
POSTERABSTRACTS

2. Methods: Demographic and clinical profile of 123 adult victims of Out-Of- Hospital
Cardiac Arrest reported in Warangal,Telangana,India was studied. Information about the
age, sex, time of cardiac arrest, risk factors: diabetes, hypertension, tobacco use, family
history, physical inactivity, prior symptoms,prior symptoms within 24 hours of cardiac
arrest, duration between prior symptoms and cardiac arrest, witnessing or not of cardiac
arrest, place of cardiac arrest were studied.
Data was entered into MS Excel. Statistical analysis was done using MedCalc Statistical
Software version 15.6.1.Appropriate analysis of Quantitative variables with normal and
non-normal distribution and categorical variables was done.
Results:
1. Males are preponderant compared to females.
2. Mean age of OOHCA is 57 years and is not differing between both sexes.
3. Age groups 40 to 59 years and !60 years are mainly affected. OOHCA is uncommon
below 40 years.
4. Majority have at least one of the five risk factors (DM,HTN,Family History, Tobacco
Use and Physical inactivity).
5. OOHCA is common during day time, specifically 6:30 AM to 11:30 AM.
6. Majority had prior symptoms within 24 hours which were communicated to their
attendants but had no cardiac check up.
7. Majority of OOHCA instances were witnessed and occurred at home.
8. Duration between prior symptoms and cardiac arrest (n¼80): Median 10minutes
(95% CI 5 to 30 minutes).
9. Preceding Symptoms more than 24 hours (n¼14): Mean: 26.6 days, SEM: 9.4.
Conclusion:
1. Persons above 40 years with cardiac symptoms and risk factors are at risk for Out- Of-
Hospital Cardiac Arrest.
2. Preventive cardiac interventions among people aged ! 40 years with risk factors and
prior symptoms are encouraged to prevent Out- Of- Hospital Cardiac Arrest.
3. The median time of 10 minutes between symptoms and Out- Of Hospital Cardac
Arrest calls for a need to improve bystander resuscitation efforts and Emergency
Medical Response services in the community.
4. The results of the study call for increasing awareness on Cardiovascular Health and
Cardiac Arrest among the population.
Disclosure of Interest: None Declared
PM081
Barriers to Cardiovascular Disease Secondary Prevention Care in The West Bank,
Palestine – A Health Professional Perspective
V. J. Collier*1
1
Department of Social Science, Health & Medicine, King’s College London, London, United
Kingdom
Introduction: Non-communicable diseases (NCDs) are fast-becoming a global burden on
health due to the rise in the rates of conditions such as cardiovascular disease (CVD). This
has become increasingly noticeable in developing countries. There is a dearth of earlier
studies relating specifically to patients and their capacity for risk factor behaviour change
within secondary care settings.
Objectives: (1) ascertaining whether health professionals consider there are specific bar-
riers for patients in the OPT to participate in lifestyle changes which may improve health
outcomes from a cardiovascular event; (2) determining which risk factors for cardiovascular
disease hinder patients to change their health behaviour; (3) determining what the barriers
and their causes may be; (4) investigating what action, if any, according to health pro-
fessionals, can be taken and by whom, to overcome any identified barriers to care at a
system- level or at an individual patient-level approach.
Methods: A study was carried out in the West Bank of Palestine using semi-structured
qualitative interviews to seek health professionals’ views on barriers for patients in the West
Bank to participate in lifestyle changes relating to CVD.
Results: The current Israeli occupation affects the Palestinian people at both an individual
and a system-level approach. Stress is considered both a risk factor for CVD, and a barrier
to health behaviour change. Poor communication exists between primary and secondary
care services, and primary care facilities are not providing adequate intervention to support
the detection and management of risk factors for CVD.
Conclusion: This study has provided some insight into how people’s health behaviours are
affected by social determinants of health and why behaviour change may be difficult.
Similar studies within primary care services, and with patients themselves, may help to
inform future health options for collaborative working aimed at addressing CVD in the
region. To be effective, however, attention also needs to be given towards a solution for
political change.
Disclosure of Interest: None Declared
PM082
Interventions to Improve Medication Adherence in Coronary Disease Patients: A
Systematic Review of Randomised Controlled Trials
K. Santo*1,2
, S. Kirkendall2
, T. Laba1,2
, J. Thakkar1,2,3
, R. Webster1,2
, J. Chalmers1,2
,
C. K. Chow1,2,3
, J. Redfern1,2
1
The George Institute for Global Health, 2
University of Sydney, 3
Westmead Hospital, Sydney,
Australia
Introduction: Medication adherence is a cornerstone of coronary heart disease (CHD)
management and prevention. However, adherence to these life-saving cardiovascular (CV)
medications is still sub-optimal worldwide and, therefore, interventions to improve
adherence are needed.
Objectives: This systematic review aimed to examine whether such interventions improved
patients’ adherence to multiple CV medications in a CHD population.
Methods: Randomised controlled trials were identified by searching multiple databases and
reference lists. Studies were selected if they evaluated any type of intervention aiming to
improve adherence to multiple CV medications targeting a population of adults with
established CHD and if they provided an appropriate measure of adherence. Interventions
were classified as complex or simple interventions based on the number of intervention
components, based on pre-specified categories. Risk ratios of being adherent were calcu-
lated where possible.
Results: Sixteen studies (10,706 patients) were included in this review. Methodological
heterogeneity precluded quantitative data synthesis. The interventions varied widely and
had mixed results. The majority of the interventions were complex with several com-
ponents (Table 1). Only seven trials achieved statistically significant higher adherence in
the intervention group. Less than a third of the complex intervention trials was associ-
ated with improvements in adherence. Three trials used single-component interventions
(text-messages reminders, polypill and financial incentives) and were successful in
GHEART Vol 11/2S/2016 j June, 2016 j POSTER/WCC_2016-POSTERS e83
POSTERABSTRACTS